ERNA vs. RENB, ARTV, OTLK, VNRX, PEPG, ATNM, STTK, ICCC, VRCA, and OKYO
Should you be buying Eterna Therapeutics stock or one of its competitors? The main competitors of Eterna Therapeutics include Renovaro (RENB), Artiva Biotherapeutics (ARTV), Outlook Therapeutics (OTLK), VolitionRx (VNRX), PepGen (PEPG), Actinium Pharmaceuticals (ATNM), Shattuck Labs (STTK), ImmuCell (ICCC), Verrica Pharmaceuticals (VRCA), and OKYO Pharma (OKYO). These companies are all part of the "pharmaceutical products" industry.
Eterna Therapeutics vs.
Eterna Therapeutics (NASDAQ:ERNA) and Renovaro (NASDAQ:RENB) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, community ranking, dividends, earnings, profitability and institutional ownership.
Renovaro has a net margin of 0.00% compared to Eterna Therapeutics' net margin of -7,513.88%. Eterna Therapeutics' return on equity of 0.00% beat Renovaro's return on equity.
Eterna Therapeutics has a beta of 5.61, meaning that its stock price is 461% more volatile than the S&P 500. Comparatively, Renovaro has a beta of 0.62, meaning that its stock price is 38% less volatile than the S&P 500.
In the previous week, Renovaro had 4 more articles in the media than Eterna Therapeutics. MarketBeat recorded 4 mentions for Renovaro and 0 mentions for Eterna Therapeutics. Eterna Therapeutics' average media sentiment score of 0.00 beat Renovaro's score of -0.21 indicating that Eterna Therapeutics is being referred to more favorably in the media.
Eterna Therapeutics has higher revenue and earnings than Renovaro. Renovaro is trading at a lower price-to-earnings ratio than Eterna Therapeutics, indicating that it is currently the more affordable of the two stocks.
Eterna Therapeutics and Renovaro both received 0 outperform votes by MarketBeat users.
70.6% of Eterna Therapeutics shares are held by institutional investors. Comparatively, 71.4% of Renovaro shares are held by institutional investors. 4.5% of Eterna Therapeutics shares are held by company insiders. Comparatively, 21.7% of Renovaro shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
Eterna Therapeutics and Renovaro tied by winning 6 of the 12 factors compared between the two stocks.
Get Eterna Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ERNA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Eterna Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ERNA) was last updated on 5/22/2025 by MarketBeat.com Staff
Buy ERNA Stock Free ERNA Stock Alerts